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Abstract: Overt hypothyroidism is implicated in atherosclerosis through dyslipidemia, hypertension, and hyperhomoscysteinemia.
Epidemiological data related to the role of thyroid hormones in the risk of coronary heart disease (CHD) and metabolic syndrome
(MS) in Turkish adults are lacking. Thyroid stimulating hormone (TSH) was measured in the 2004 follow-up of the Turkish Adult
Risk Factor Study, with the aim of investigating thyroid hormone status as a possible risk factor in CHD and MS in the population
sample. To this end, a subgroup of the cohort (512 men and women: mean age 52 ± 11.4) in whom the prevalences for CHD, MS
and diabetes (DM) were 8.2%, 42.4% and 10.7%, respectively, were screened for TSH. The cohort was classified as hypo-, hyperor euthyroid according to cutoffs of 4.2 and 0.3 µU/ml for TSH, respectively. No distinction was made between overt and subclinical
thyroid states.
Total and LDL-cholesterol was lowest, but waist circumference unexpectedly highest in the hyperthyroid group. Women (1.3 µU/ml)
had significantly higher (P < 0.001) TSH levels than men (0.95 µU/ml). The prevalence of hypo- and hyperthyoidism in men and
women were 1.7%/7% and 4.4%/5%, respectively, and women overwhelmingly predominated the hypothyroid cases. TSH values
did not significantly differ among groups diagnosed as or not CHD, MS, or DM. Log TSH was significantly correlated with total and
LDL-cholesterol and, inversely, with alcohol usage. Multivariate linear regression analysis revealed total cholesterol as the sole
independent covariate of TSH levels in men and both sexes combined. An increase by approximately one-third of the physiological
TSH levels was associated with a 40 mg/dl-increase in total cholesterol concentrations. Age- and sex-adjusted TSH did not contribute
to the risk of CHD, hypercholesterolemia, MS, or DM in logistic regression analyses.
To conclude, TSH levels were independently associated with total cholesterol concentrations but did not appear to be a risk factor
for CHD or MS in the cohort studied. Following up the group prospectively may give a better understanding concerning the thyroid
status and CHD risk in Turkish adults.
Key Words: Coronary disease risk; serum TSH; thyroid status

Introduction
Hypothyroidisim is associated with cardiovascular risk
(1,2). Log linear relation between free thyroxine (fT4)
and thyroid stimulating hormone (TSH) makes TSH the
first choice for diagnosis of thyroid dysfunction (3).
Subclinical excess or deficiency of thyroid hormones can

be diagnosed only by serum levels of TSH.
Hypothyroidism prevalence is reported as 1-10% in
adults (4) and can reach 20% (5) in the elderly, especially
women. Subclinical dysthyroidism is defined by abnormal
circulating TSH values in face of normal free thyroid
hormone levels (5). Subclinical hypothyroidism,
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characterized by modifications in cardiovascular and
neuromuscular functions and lipid metabolism, may be
the first phase or beginning of a progressive disease state
(6,7). Small changes in thyroid function tests within the
reference range influence the severity of atherosclerosis
(1). In thyroid defiency, hypertension together with
dyslipidemia accelerate atherosclerosis (8). Both
hypothyroidism and subclinal hypothyoidsm are
associated with hyperhomocyteinemia, endothelial
dysfunction, left ventricular dysfunction and mild
inflammation characterized by elevated C-reactive proten
(CRP) levels, and defective coagulation (9,10). The
similarities in cardiovascular anomaly pattern in HT and
SCHT imply that even small deficiencies in thyroid
hormones may have effects on the cardiovascular system.
Studies also exist (11-13) that found no associations
between SCTH and cardiovacular events and lipid profiles.
The basic reason for conflicting results is the gradual
decline in TSH upper reference limit over the last two
decades from ~ 10 to ~4.0-4.5 µU/ml.
Low TSH levels also have effects on the cardiovascular
system (14). Even a single measurement of low TSH in
individuals aged 60 or older was associated with
mortality from all causes and, particularly, cardiovascular
disease (15).
We aim in this paper to report in a limited population
sample of just over half of Turkey’s population a) the
prevalences of surrogates of hypo- or hyperthyroidism,
b) the associations of TSH levels with cardiovascular risk
factors as well as with coronary heart disease (CHD) and
metabolic syndrome (MS).
Material and Methods
Population sample
TSH was measured in 512 men and women within the
cohort of the 2004 follow-up of the Turkish Adult Risk
Factor Study conducted in the Aegean, Mediterranean,
East and Southeast Anatolia and Black Sea regions.
Participants were 34 years of age or older. The survey
was representatively stratified for sex, age, geographical
regions and for rural-urban distribution. Informed
consent was obtained from each individual, and the
survey conformed to the principles embodied in the
Declaration of Helsinki. Data were obtained by history of
the past years via a questionnaire, physical examination of
the cardiovascular system and recording of a resting
electrocardiogram (ECG) (16).
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Identification of MS conformed to the definition used
by the NCEP guidelines (17), namely when 3 or more of
the following 5 risk determinants were present: waist
circumference (men >102 cm, women >88 cm),
triglycerides ≥150 mg/dl, HDL-cholesterol (men <40,
women <50 mg/dl), blood pressure (≥130/≥85 mmHg),
and fasting glucose ≥110 mg/dl.
Measurement of risk factors and validation
Blood pressure was measured twice in the sitting
position on the right arm using a sphygmomanometer
(Erka), after at least 5 minutes of rest. Readings were
recorded to the nearest even number, and the mean of
two recordings 3 min apart was computed. Waist
circumference was measured - with the subject standing
and wearing only underwear, at the level midway
between the lower rib margin and the iliac crest, while
that of the hip was measured at the level of the great
trochanters. Body mass index (BMI) was calculated by the
computer as weight divided by height squared (kg/m2). In
regard to cigarette smoking, nonsmokers, past smokers
and current smokers formed the categories.
Plasma concentrations of cholesterol, fasting
triglycerides, HDL-cholesterol (HDL-C) and glucose were
determined by the enzymatic Roche kits, uric acid by
Infinity kits, γ-glutamyl transferase (GGT) by Thermo
Trace kinetic kit, and phospholipids by WAKO phosholipid
B kit using Hitachi 902 autoanalyzer. TSH and insulin
were measured by chemiluminescence immunoassay
“ECLIA”
method
utilising
Elecsys
1010
immunautoanalyzer. Concentrations of apo A-I, apo B,
hs-CRP and complement C3 were measured by means of
particle-enhanced immunonephelometry with the Behring
nephelometer method using N Latex CRP mono reagent
(Behring Diagnostics). Within run and day to day CV for
TSH were 3.4/3.2% and 5.0/4.2%, respectively, and
<1.7 and 2.4% for biochemistry parameters on Hitachi,
< 3.1 and 4.4% for the blood proteins measured with
the nephelometer, respectively, for the two-level control
sera. The laboratory was a member of an external quality
control program. Mean values given for concentrations of
TSH, GGT and CRP are geometric means calculated from
the log-transformed distribution.
Individuals with diabetes mellitus or impaired fasting
glucose were identified by self report or by adhering to
the criteria of the American Diabetes Association (18).
LDL-cholesterol values were computed according to the
Friedewald formula (19).
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TSH reference limits were taken as 0.3 and 4.2
µU/ml, as provided by the manufacturing firm. Values
within the limits were evaluated as euthroid whereas
those above 4.2 µU/ml as hypothyroid, and below 0.3
µU/ml as hyperthyroid. Becuase fT4 levels were not
measured, we made no distinction between subclinical
and overt thyroid dysfunction. Participants were
questioned about acute or chronic diseases and
medications. None reported having used medications
(glucocorticoids or dopamine) that decreased or
(amiodarone or lithium) increased TSH (3).

Diagnosis of CHD was based on the presence of
angina pectoris, a history of myocardial infarction with or
without accompanying Minnesota codes of the ECG (20),
or a history of myocardial revascularization. Retrosternal
or precordial distress coming on exertion, lasting 2-15
minutes and relieved by rest was designated as typical
angina, while in the absence of the last feature this was
considered as atypical angina. Among women typical
angina before 45 years and atypical angina at any age
precluded the diagnosis. Isolated typical angina in women
and atypical angina in men were considered as suspect
diagnosis. These criteria resulted in the fact that ECG
changes of “ischemic type” of greater than minor degree
(Codes 1.1-2, 4.1-2, 5.1-2, 7.1) were associated in over
three-fifths of all patients. A cerebrovascular accident
(CVA) was diagnosed when a new stroke occurred, or
when death followed such an event.
Anyone consuming alcohol once a month or more
were evaluated as alcohol users. Smokers were classified
as nonsmokers, past or current smokers. Physical activity
was classified as 1. white collar worker, sewing or
knitting, 1 km daily walk 2-repair worker 1-2 km daily
walk , 3-carpenter, floor and window cleaning, truck
driving, 4 km daily walk, 4- heavy work, farming and
regular sports activity .
Venous blood was centrifuged at 3000 rpm for 15
minutes to separate within one hour from its cells to
obtain sera. Sera were sent to ‹stanbul on ice packs and
kept at -80° C until the day of measurements.
Measurements were made at Yildiz Technical University
Medical Center Laboratory.
Data analysis
The independent associations between risk variables
and CVD were evaluated by logistic regression. Relative
risk estimates and 95% confidence intervals were

obtained. Regression models were adjusted for
confounding variables (age, sex, etc.). Due to the skewed
distribution of TSH, CRP, fasting insulin and GGT values,
these parameters were log-transformed for calculations.
Two-sided t-tests and Pearson’s chi-square tests were
used to analyze the differences in proportions between
groups at the last follow-up examination. A value of P <
0.05 was considered statistically significant. Univariate
correlation analyses were performed according to
Pearson. Multiple regression analyses of the data were
carried out using SPSS-10 for Windows package.

Results
Mean TSH values for genders and age groups are
shown in Table 1. Median values (and interquartile
intervals) for men were 1.05 (0.68-1.62) and for women
1.40 (0.84-2.22) µU/ml, respectively. Geometric mean
TSH value for women (1.3 µU/ml) was significantly (P <
0.001) higher than that of men (0.95 µU/ml). Mean TSH
values were not different either across geographic
regions or between those younger or older than 60 years.
Low, normal and high TSH prevalences in our cohort
were 4.7%, 91%, and 4.4%, respectively. Women
constituted 82.6 % of the hypothyroids. Seven percent of
women, as contrasted to only 1.7% of men, were
hypothyroid. In the high TSH group (hypothyroid, Group
III) distribution of genders were significantly different (P
< 0.015).
General characteristics of the low, normal, and high
TSH groups are given in Table 2. Three groups were first
compared with Kruskal Wallis analysis and then with
Mann Whitney U test two by two, whenever a significant
difference was found with the former. The only
significantly different parameters were high waist-to-hip
ratio and low total cholesterol and HDL-phospholipid in
the low TSH (Group I) compared to the normal TSH
group (II).
CHD, MS and DM were diagnosed in 42 ( 8.2%), 217
(42.4 %), 55 (10.7%) of the participants in this study
(Table 3). Neither the TSH mean values, nor the
prevalences of low or high TSH were significantly
different in those who were diagnosed as CHD, MS, and
DM or not. Smoking frequency was 13, 12.5, and 26%
in the high, low, and normal TSH groups.
Correlations between the risk parameters and TSH
were found in men only with total cholesterol (r = 0.21),
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Table 1. TSH geometric mean values by gender and age groups in 512 Turkish adults (µU/ml)
Men
Age groups

Women

n

mean

SD

n

mean

SD

34-49
50-59
60-69
>70

107
61
43
28

0.95
1.08
0.76
1.01

2.31
1.91
4.36
2.65

133
67
49
24

1.37
1.42
1.14
1

2.4
2.86
3.2
3.43

Total

239

0.95

2.61

273

1.3

2.74

Table 2. General characteristics of the groups with low, normal, and high TSH levels

Gender: women (%)
Age (years)
TSH* µU/ml

Group I

Group II

Group III

TSH<0.3 µU/ml

TSH:0.3-4.19 µU/ml

TSH:>4.2 µU/ml

n = 24

n = 465

n = 23

12 (50)

242 (52.0)

19 (82.6)

55.6 ± 11.7

51.9 ± 11.5

50.1 ± 10.1

0.06 ± 4.3

1.12 ± 1.8

7.54 ± 1.6

Waist circumference (cm)

100.1 ± 12.2 *

95.4 ± 10.5

93.0 ± 10.5

Waist/hip ratio

0.98 ± 0.06***

0.94 ± 0.09

0.93 ± 0.07

Body mass index

(kg/m2)

Systolic BP (mmHg)
Diastolic BP (mmHg)
Total cholesterol (mg/dl)

30.7 ± 6.1

29.3 ± 4.5

29.0 ± 4.2

130.1 ± 24.7

126.5 ± 20.6

121.6 ± 23.8

83.4 ± 12.3

80.9 ± 10.9

78.8 ± 13.2

173.5 ± 39.0 *

195.0 ± 44.5

197.2 ± 40.9

HDL-cholesterol (mg/dl)

41.2 ± 9.2

44.1 ± 12.2

44.8 ± 11.5

LDL-cholesterol (mg/dl)

101.3 ± 31.5 #

113.7 ± 37.7

118.0 ± 34.7

Triglycerides (mg/dl)

134.6 ± 71.4

170.4 ± 109.6

160.0 ± 98.7

Glucose (mg/dl)

100.1 ± 22.4

103.8 ± 41.31

101.8 ± 27.21

Uric acid (mg/dl)

5.37 ± 1.97

5.2 ± 1.5

4.36 ± 1.36

Gamma GT Ψ (U/l)

27.7 ± 2.5

20.2 ± 1.8

18.2 ± 2.0

Total phospholipids (mg/dl)

200.3 ± 50.5

211.1 ± 42.1

209.3 ± 36.0

HDL-phospholipids (mg/dl)

112.2 ± 19.6**

138.4 ± 35.8

146.0 ± 39.1

2.57 ± 3.16

2.46 ± 2.88

2.46 ± 2.95

Apolipoprotein A-I (mg/dl)

157.6 ± 43.5

137.9 ± 31.4

131.7 ± 18.2

Apolipoprotein B (mg/dl)

106.4 ± 22.2

106.1 ± 30.9

94.7 ± 25.9

Complement C3 (g/L)

1.44 ± 0.3

1.35 ± 0.33

1.36 ± 0.28

Fasting insulin Ψ (µU/ml)

8.12 ± 1.74

8.31 ± 1.95

9.12 ± 2.29

Fibrinogen (g/L )

3.17 ± 0.98

hs-C-reactive protein (mg/L)

3.30 ± 0.54

3.36 ± 1.04

Coronary heart disease (%)

12.5

7.7

13.0

Metabolic syndrome (%)

54.2

41.7

43.5

Diabetes mellitus (%)

4.2

11.4

4.4

BP: blood pressure, HDL: high-density lipoprotein, LDL: low-density lipoprotein
Ψ: log transformed values
significant difference between the related group and group II: * (P < 0.05), ** (P < 0.01), ***(P < 0.001),
# (p = 0.086)
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Table 3.

TSH geometric means and prevalence rates of low, normal and high TSH in groups with or without coronary heart disease, metabolic
syndrome or diabetes

N

TSH
Mean ± SD

low TSH
<0.3 U/L
(%)

normal TSH
0.3-<4.2
(%)

high TSH
≥4.2 U/L
(%)

Men
Women

239
273

0.96 ± 2.61*
1.30 ± 2.75

5
4.4

93.3
88.6

1.7
7.0 #

CHD present
CHD absent

42
470

1.04 ± 3.38
1.13 ± 2.65

7.2
4.5

85.7
91.3

7.1
4.3

MS present
MS absent

217
295

1.12 ± 3.17
1.13 ± 2.39

6
3.7

89.4
91.9

4.6
4.4

Diabetes present
Diabetes absent

55
457

1.08 ± 2.28
1.13 ± 2.77

1.8
5

96.4
90.2

1.8
4.8

* P < 0.001 ; with # Chi square test p = 0.015
CHD:coronary heart disease, MS:metabolic syndrome

LDL-cholesterol (r = 0.21) and, inversely, with alcohol
usage (r = -0.15) (Table 4). No correlation existed
between age or smoking status and log TSH in either
gender. Total cholesterol (r = 0.004) and, inversely,
alcohol intake status (r = -0.196) were obtained as the
only two significant independent predictors of TSH in
multivariate linear regression analyses in adults or men
(Table 5); no independent covariate of TSH was found for
women. Our finding of the multivariate analysis implied
that a 40 mg/dl (1 SD of total cholesterol) increase in
total cholesterol corresponded to a 0.32 µU/ml-increase
(1/3 of the physiological level) in TSH values. A model
which included age, waist circumference, diastolic blood
pressure, and GGT was also significant but could explain
only 3% of the TSH variance.

Discussion

Age- and gender-adjusted TSH elevations (>4.2
µU/ml) did not contribute to the risk of
hypercholesterolemia (>200 mg/dl), CHD, or MS by
logistic regression analyses (Table 6).

No distinction was made between subclinical and overt
thyroid status in our study group because free T4 was
not measured. Adult hypothyroidism overwhelmingly
(>99%) stems from primary thyroid insufficiency, a

Lacking population-based data in regard to thyroid
function status and its relation with CHD and its risk
factors among Turkish adults, thyroid function was
assessed by TSH measurement in this cross-sectional
study. The TSH method used, having a functional
sensitvity of <0.020 µU/ml, was suitable for screening
for primary hypo- or hyperthyroidism, whether overt or
subclinical (3). Main findings of our study were
prevalences of hypo- or hyperthyroidism ranging around
4-5%, a 4-fold higher prevalence of hypothyroidism in
women than in men, significant independent associations
of TSH with total cholesterol and alcohol abstinence, and
lack of association with CHD of (gender- and ageadjusted) high TSH levels.

Table 4. Significant correlations of TSH with risk factors
Men + women

Men

Women

r

p

p

p

Total cholesterol (mg/dl)

0.172

0.000

0.211

0.001

0.104

LDL-cholesterol (mg/dl)

0.168

0.000

0.208

0.002

0.107

0.080

Alcohol usage (0-3)

-0.137

0.002

-0.148

0.024

-0.008

0.899

0.087
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Table 5. Determinants of serum TSH by multiple linear regression (n = 456)

Adults

Men

Women

β coeffic.

SE

p

β coeffic.

SE

p

β coeffic.

SE

p

- 0.005
-0.009
0.005
0.012
-0.391
-0.284

0.008
0.009
0.002
0.009
0.347
0.152

0.566
0.284
0.013
0.172
0.259
0.062

0.005
-0.008
0.007
0.007
-0.462
-0.167

0.009
0.009
0.002
0.010
0.402
0.124

0.570
0.384
0.004
0.471
0.252
0.178

-0.009
-0.010
0.002
0.015
0.088
-0.183

0.014
0.014
0.003
0.014
0.570
0.587

0.528
0.395
0.482
0.280
0.877
0.755

Age
Waist circumference (cm)
Total cholesterol (mg/dl)
DBP (mm Hg)
Log gamma GT (U/L)
Alcohol usage (0-3)

Model was significant for adults and men (p = 0.024 and p = 0.047, respectively); explained 6% of variance in men.

Table 6.

Odds ratio of age- and gender-adjusted TSH for prevalent coronary heart disease and hypercholesterolemia (compared to normal or low
TSH values [n = 510])
Coronary heart disease
β

OR

Age (years)

0.097

1.102

0.000

Gender(M)

-0.298

0.742

NS

1.013

2.754

0.151

Adults

TSH (>4.2 µU/ml)

p

Hypercholesterolemia
β

OR

p

95% CI

1.067; 1.14

0.029

1.029

0.000

1.013; 1.046

0.625

1.867

0.001

1.29; 2.70

0.691; 11.0

-0.008

0.992

NS

95% CI

Model included 512 men and women and 42 coronary heart disease patients
Model included 512 men and women and 96 hypercholesterolemic (>200 mg/dl) individuals
CI: confidence interval, M: males

disorder which is usually accompanied by above-normal
TSH levels (3,4).

with the knowledge that the likelihood of a diagnosis of
thyroid dysfunction is 3-10 times higher in women (5).

The limit for an upper reference range for TSH has
declined from ~10 to 20 µU/ml to ~4 µU/ml in the last
two decades (3,4). Mean TSH levels in populations with
sufficient iodide intake are around 1.5 µU/ml, and the
reference range is often given as 0.4-4.0 µU/ml. The
American Association of Clinical Endocrinologists, in their
2002 Guidelines, has recommended 0.3-3.0 µU/ml as the
target range for TSH levels (12).

Although 43% of the hypothyroid group was
hypercholesterolemic (>200 mg/dl), the prevalence of
hypothyroidism
was
not
different
in
the
hypercholesterolemic group (4.9%) from that of the
whole group. In men, however, total cholesterol
increased significantly as TSH levels rose, independently
of age and other risk parameters investigated. An
increase by approximately one-third of the physiological
TSH levels was associated with a 40 mg/dl-increase
(about one-fifth) in total cholesterol concentrations,
independent of several other risk variables. This is a
salient finding of the present study reflecting the
dimension of interrelationship between levels of TSH and
total cholesterol.

Different reference ranges accepted in different
studies have led to conflicting findings and prevalence
data (21-23). Hypothyroidism is a common disorder with
a prevalence ranging from 1 to 10% of the adult
population with increasing frequency in women and the
elderly, while that of subclinical hypothyroidism reaches
20% in persons beyond 60 years of age.
Hypothyroidism accounts for 80% of all thyroid
dysfunctions. In our cohort, it was 4 times more
prevalent in women than in men. This is in agreement
302

It is known that hypothyroidism can contribute to a
50%-increase in total cholesterol levels (24) and dispose
apoE2 allele carriers to a type III dyslipidemia especially in
obese hypothyroid individuals (25). Thyroid hormones
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affect lipoprotein metabolism through their effects on
cholesterol ester transfer protein, hepatic lipase,
lipoprotein lipase, and HMG CoA reductase (26). Both
fatty acids and LDL oxidation promotes hypothyroidism
(27).
In a study conducted on 300 dyslipidemic Turkish
men and women, prevalences of SCHT and HT were
found as 10.6% and 2.6%, respectively. In combined
hiperlipidemia these ratios inreased to 16.2% and 7.5%,
respectively (28). Dyslipidemia was detected in 91.4% of
the 268 overt hypothroid patients in a study of the Mayo
Clinic (29). In SCHT patients, however, no increase in
basal total cholesterol was found in a large study with
over 1000 SCHT and 5000 euthyroid controls (13). We
observed no significant increase in total cholesterol
concentrations in the hypothyroid group; by contrast
total cholesterol and HDL-phospholipids were significantly
lower in the hyperthyroid than in the euthyroid group.
It was reported in the NHANES Phase III survey that
total cholesterol (but not LDL-cholesterol) was higher and
HDL-cholesterol lower in SCHT patients, compared to
euthyroid controls. In this study on 8222 adults past age
40 years, the TSH interval to define SCHT was taken as
6.7-14.9 µU/ml. Yet, after adjustments for age, ethnicity,
gender and lipid lowering medication, SCHT was no
longer associated with raised total cholesterol or
triglycerides (12).
Hypothyroidism has been reported to contribute to
CHD via hyperhomocysteinemia and hypercholesterolemia
(30,31). Cardiovascular disease was recently reported to
be predicted by SCHT in men younger than 50 years of
age, in whom elevation in plasma triglycerides and lowgrade inflammation were associated; the disease being
3.4 times higher, compared to euthyroid men (32). SCHT
may be associated not only with ischemic events but also
with all-cause mortality (33).

diastolic blood pressure and serum GGT, the independent
association of alcohol consumption retained a borderline
significance (p = 0.062), except when gender was also
added to the adult model. Evidence was shown for a
flattening effect of high-dose alcohol intake on the
nocturnal TSH secretion and modification of its circadian
rhythm (34). It would be of interest to investigate the
effect of alcohol in a larger group in our future surveys.
The lack of associations in this study between
smoking status or age and TSH levels may result from a
small sample size, since smoking has been noted to be
associated with higher TSH levels and lower fT4, and
thyroid dysfunction is known to increase with age,
especially in women (3).
To conclude, the prevalence of hypothyroidism was
7% in women and 1.7% in men with TSH when an upper
reference limit was considered as 4.2 µU/ml. TSH
correlated significantly and independently with total
cholesterol, and at a borderline significance, inversely,
with alcohol intake. TSH did not contribute to CHD, MS,
or DM, probably due to a small sample size. TSH
measurements do not justify screening for thyroid
function with the purpose of preventive action in the
general population, but only in individuals at high-risk for
hypothyroidism (including those above middle age).
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